Original research
par
Jutras-Aswad, Didier et al
Date de publication
2022
Géographie
Canada
Langue de la ressource
English
Texte disponible en version intégrale
Oui
Open Access / OK to Reproduce
Non
Évalué par des pairs
Yes
L’objectif
The authors aimed to determine whether flexible take-home buprenorphine/naloxone is as effective as supervised methadone in reducing opioid use in prescription-type opioid consumers with opioid use disorder.
Constatations/points à retenir
The buprenorphine/naloxone flexible model of care was safe and noninferior to methadone in reducing opioid use among people with prescription-type opioid use disorder. Participants in the buprenorphine/naloxone group had 0.47 times the odds (95% CI=0.24, 0.90) of being retained in the assigned treatment compared with those in the methadone group.
La conception ou méthodologie de recherche
Seven-site, pan-Canadian, 24-week, pragmatic, open-label, noninferiority, two-arm parallel randomized controlled trial (n=272)
Mots clés
Substitution/OAT
About PWUD
Outcomes
Carries/take-home doses
